TRADING UPDATES: Vaalco says remainder of 2026 to be "very profitable"
(Alliance News) - The following is a round-up of updates by London-listed companies, issued last Wednesday and not separately reported by Alliance News: Read More
| Price | 88.50p on 14-05-2026 at 08:00:02 |
|---|---|
| Change | -0.50p -0.56% |
| Buy | 90.00p |
| Sell | 87.00p |
| Last Trade: | Sell 3,402.00 at 88.3111p |
| Day's Volume: | 250,902 |
| Last Close: | 89.00p |
| Open: | 89.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 88.50p - 89.00p |
| 52wk Range: | 27.25p - 90.50p |
| Market Capitalisation: | £401.35m |
| VWAP: | 88.60776p |
| Shares in Issue: | 453.51m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 3,402 | 88.3111p | Ordinary |
08:58:22 - 14-May-26 |
| Buy* | 10,000 | 88.70p | Ordinary |
08:55:54 - 14-May-26 |
| Buy* | 1,122 | 88.80p | Ordinary |
08:49:32 - 14-May-26 |
| Sell* | 4,061 | 88.2555p | Ordinary |
08:48:14 - 14-May-26 |
| Sell* | 1,022 | 88.2555p | Ordinary |
08:47:19 - 14-May-26 |
| Sell* | 483 | 88.2511p | Ordinary |
08:46:49 - 14-May-26 |
| Buy* | 2,245 | 88.844p | Ordinary |
08:44:20 - 14-May-26 |
| Buy* | 840 | 88.8956p | Ordinary |
08:37:47 - 14-May-26 |
| Buy* | 1,124 | 88.8956p | Ordinary |
08:37:05 - 14-May-26 |
| Buy* | 32 | 88.8956p | Ordinary |
08:36:07 - 14-May-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 13th May 2026 7:00 am | RNS | Notice of Preliminary Results and Presentation |
| 13th May 2026 7:00 am | RNS | Issue of Equity and Total Voting Rights |
| 6th May 2026 7:00 am | RNS | Pre|CISION® payload release vs approved ADCs |
| 28th Apr 2026 7:00 am | RNS | Block Listing Six Monthly Return |
| 21st Apr 2026 7:00 am | RNS | Avacta data AACR underline AVA6103 profile |
| 14th Apr 2026 11:37 am | RNS-R | Christina Coughlin - In Vivo 2026 Rising Leader |
| 9th Apr 2026 7:00 am | RNS | Q1 2026 Business Update |
| 8th Apr 2026 7:00 am | RNS-R | Avacta Announces Science Day 2026 |
| 31st Mar 2026 7:00 am | RNS | First patient treated in Phase 1 trial of AVA6103 |
| 27th Mar 2026 7:00 am | RNS | Result of Oversubscribed Fundraise |